Lidocaína 5% Braun

Lidocaine, the active ingredient in Lidocaína 5% Braun, is a local anesthetic presented as a 5% injectable solution for epidural, intramuscular, and intravenous use. It provides local anesthesia and analgesia in surgical and procedural settings.

GNH USA supplies Lidocaína 5% Braun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is used to achieve local anesthesia and analgesia in various clinical settings.

- Surgical procedures: provides regional or local anesthesia to facilitate surgery - Labor and delivery: used for epidural analgesia to reduce pain during childbirth - Diagnostic procedures: numbs tissue for minor surgeries or catheter insertions

Adverse reactions may range from mild, transient events to rare but serious complications.

Common Side Effects: - Transient burning or stinging at the injection site - Mild dizziness or light‑headedness - Nausea or vomiting - Metallic taste in the mouth - Localized swelling or erythema - Headache

Serious or Rare Side Effects: - Seizures or convulsions - Cardiac arrhythmias, including ventricular tachycardia - Severe hypotension or cardiovascular collapse - Allergic reactions such as anaphylaxis - Methemoglobinemia - Persistent neurologic deficits

Before administration, clinicians should consider several safety measures.

- Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics - Cardiovascular status: avoid in patients with severe heart block or conduction disorders - Neurological conditions: use cautiously in patients with epilepsy or seizure disorders - Dosage limits: adhere to recommended maximum dose to prevent systemic toxicity - Concurrent CNS depressants: monitor for additive sedative effects - Store at room temperature: keep in original container, protect from light and moisture

Lidocaine may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma levels and toxicity risk - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can reduce lidocaine metabolism leading to accumulation

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance cardiac depressant effects of lidocaine - General anesthetics (e.g., propofol, volatile agents): additive central nervous system depression - Diuretics (e.g., furosemide): may alter plasma protein binding and increase free drug concentration - Other local anesthetics: concurrent use raises cumulative toxicity potential